{
  "DOI": "10.1007/s10689-021-00277-7",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-021-00277-7",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eAccording to current guidelines, all women with epithelial ovarian cancer are eligible for genetic testing for \u003cjats:italic\u003eBRCA\u003c/jats:italic\u003e germline pathogenic variants. Unfortunately, not all affected women are tested. We evaluated the acceptability and feasibility for non-genetic healthcare professionals to incorporate germline genetic testing into their daily practice. We developed and implemented a mainstreaming pathway, including a training module, in collaboration with various healthcare professionals and patient organizations. Healthcare professionals from 4 different hospitals were invited to participate. After completing the training module, gynecologic oncologists, gynecologists with a subspecialty training in oncology, and nurse specialists discussed and ordered genetic testing themselves. They received a questionnaire before completing the training module and 6 months after working according to the new pathway. We assessed healthcare professionals’ attitudes, perceived knowledge, and self-efficacy, along with the feasibility of this new mainstream workflow in clinical practice, and evaluated the use and content of the training module. The participation rate for completing the training module was 90% (N = 19/21). At baseline and after 6 months, healthcare professionals had a positive attitude, high perceived knowledge and high self-efficacy toward discussing and ordering genetic testing. Knowledge had increased significantly after 6 months. The training module was rated with an average of 8.1 out of 10 and was considered useful. The majority of healthcare professionals (9/15) was able to discuss a genetic test in five to 10 min. After completion of a training module, non-genetic healthcare professionals feel motivated and competent to discuss and order genetic testing themselves.\u003c/jats:p\u003e",
  "alternative-id": [
    "277"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "16 April 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "28 September 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "7 October 2021"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "K. Bokkers, R.P. Zweemer, M.J. Koudijs, S. Stehouwer, M.E. Velthuizen, and E.M.A. Bleiker have nothing to disclose.M.G.E.M. Ausems received a grant from AstraZeneca for development and filming of the training module. AstraZeneca was not involved in the development of its content."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "This study was reviewed by the Medical Review Ethics Committee (MREC) of the UMC Utrecht in March 2018 and the Medical Research Involving Human Subjects Act (WMO) did not apply to our study and therefore official approval by the MREC was not necessary."
    },
    {
      "group": {
        "label": "Consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "Not applicable."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 5,
      "value": "Not applicable."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Bokkers",
      "given": "Kyra",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Zweemer",
      "given": "Ronald P.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Koudijs",
      "given": "Marco J.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Stehouwer",
      "given": "Sanne",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Velthuizen",
      "given": "Mary E.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-4357-949X",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Bleiker",
      "given": "Eveline M. A.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-0305-3477",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Ausems",
      "given": "Margreet G. E. M.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        10,
        7
      ]
    ],
    "date-time": "2021-10-07T03:34:27Z",
    "timestamp": 1633577667000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        6,
        16
      ]
    ],
    "date-time": "2022-06-16T07:18:49Z",
    "timestamp": 1655363929000
  },
  "funder": [
    {
      "DOI": "10.13039/100004325",
      "doi-asserted-by": "publisher",
      "name": "AstraZeneca"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        27
      ]
    ],
    "date-time": "2024-03-27T17:55:45Z",
    "timestamp": 1711562145990
  },
  "is-referenced-by-count": 15,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "3",
  "issued": {
    "date-parts": [
      [
        2021,
        10,
        7
      ]
    ]
  },
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2022,
          7
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            10,
            7
          ]
        ],
        "date-time": "2021-10-07T00:00:00Z",
        "timestamp": 1633564800000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            10,
            7
          ]
        ],
        "date-time": "2021-10-07T00:00:00Z",
        "timestamp": 1633564800000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-021-00277-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-021-00277-7/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-021-00277-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "295-304",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2021,
        10,
        7
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        10,
        7
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2022,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3322/caac.21492",
      "author": "F Bray",
      "doi-asserted-by": "publisher",
      "first-page": "394",
      "issue": "6",
      "journal-title": "CA Cancer J Clin",
      "key": "277_CR1",
      "unstructured": "Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492",
      "volume": "68",
      "year": "2018"
    },
    {
      "key": "277_CR2",
      "unstructured": "CRGO (2015) Guideline hereditary and familial ovarian cancer."
    },
    {
      "DOI": "10.1200/JCO.19.02960",
      "author": "PA Konstantinopoulos",
      "doi-asserted-by": "publisher",
      "first-page": "1222",
      "issue": "11",
      "journal-title": "J Clin Oncol",
      "key": "277_CR3",
      "unstructured": "Konstantinopoulos PA, Norquist B, Lacchetti C et al (2020) Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 38(11):1222–1245. https://doi.org/10.1200/JCO.19.02960",
      "volume": "38",
      "year": "2020"
    },
    {
      "author": "NCC Network",
      "first-page": "2019",
      "journal-title": "Version",
      "key": "277_CR4",
      "unstructured": "Network NCC (2018) NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. Version 2:2019",
      "volume": "2",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2011.39.8545",
      "author": "K Alsop",
      "doi-asserted-by": "publisher",
      "first-page": "2654",
      "issue": "21",
      "journal-title": "J Clin Oncol",
      "key": "277_CR5",
      "unstructured": "Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663. https://doi.org/10.1200/JCO.2011.39.8545",
      "volume": "30",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.ygyno.2011.01.020",
      "author": "S Zhang",
      "doi-asserted-by": "publisher",
      "first-page": "353",
      "issue": "2",
      "journal-title": "Gynecol Oncol",
      "key": "277_CR6",
      "unstructured": "Zhang S, Royer R, Li S et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121(2):353–357. https://doi.org/10.1016/j.ygyno.2011.01.020",
      "volume": "121",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.20.01924",
      "author": "WP Tew",
      "doi-asserted-by": "publisher",
      "first-page": "3468",
      "issue": "30",
      "journal-title": "J Clin Oncol",
      "key": "277_CR7",
      "unstructured": "Tew WP, Lacchetti C, Ellis A et al (2020) PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 38(30):3468–3493. https://doi.org/10.1200/JCO.20.01924",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.1001/jama.2019.10987",
      "author": "USPST Force",
      "doi-asserted-by": "publisher",
      "first-page": "652",
      "issue": "7",
      "journal-title": "JAMA",
      "key": "277_CR8",
      "unstructured": "Force USPST, Owens DK, Davidson KW et al (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA 322(7):652–665. https://doi.org/10.1001/jama.2019.10987",
      "volume": "322",
      "year": "2019"
    },
    {
      "DOI": "10.1200/JCO.2017.73.6314",
      "author": "CP Childers",
      "doi-asserted-by": "publisher",
      "first-page": "3800",
      "issue": "34",
      "journal-title": "J Clin Oncol",
      "key": "277_CR9",
      "unstructured": "Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) national estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35(34):3800–3806. https://doi.org/10.1200/JCO.2017.73.6314",
      "volume": "35",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.clon.2018.04.004",
      "author": "PJ Hoskins",
      "doi-asserted-by": "publisher",
      "first-page": "472",
      "issue": "8",
      "journal-title": "Clin Oncol (R Coll Radiol)",
      "key": "277_CR10",
      "unstructured": "Hoskins PJ (2018) Inadequate rates of BRCA testing with its negative consequences for women with epithelial ovarian cancer and their families: an overview of the literature. Clin Oncol (R Coll Radiol) 30(8):472–483. https://doi.org/10.1016/j.clon.2018.04.004",
      "volume": "30",
      "year": "2018"
    },
    {
      "DOI": "10.3390/cancers10110435",
      "author": "JM McCuaig",
      "doi-asserted-by": "publisher",
      "journal-title": "Cancers (Basel)",
      "key": "277_CR11",
      "unstructured": "McCuaig JM, Armel SR, Care M, Volenik A, Kim RH, Metcalfe KA (2018) Next-generation service delivery: a scoping review of patient outcomes associated with alternative models of genetic counseling and genetic testing for hereditary cancer. Cancers (Basel). https://doi.org/10.3390/cancers10110435",
      "year": "2018"
    },
    {
      "DOI": "10.1200/JCO.2017.76.2781",
      "author": "N Colombo",
      "doi-asserted-by": "publisher",
      "first-page": "1300",
      "issue": "13",
      "journal-title": "J Clin Oncol",
      "key": "277_CR12",
      "unstructured": "Colombo N, Huang G, Scambia G et al (2018) Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol 36(13):1300–1307. https://doi.org/10.1200/JCO.2017.76.2781",
      "volume": "36",
      "year": "2018"
    },
    {
      "DOI": "10.1038/srep29506",
      "author": "A George",
      "doi-asserted-by": "publisher",
      "first-page": "29506",
      "journal-title": "Sci Rep",
      "key": "277_CR13",
      "unstructured": "George A, Riddell D, Seal S et al (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep 6:29506. https://doi.org/10.1038/srep29506",
      "volume": "6",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.ygyno.2020.05.001",
      "author": "M Gleeson",
      "doi-asserted-by": "publisher",
      "first-page": "431",
      "issue": "2",
      "journal-title": "Gynecol Oncol",
      "key": "277_CR14",
      "unstructured": "Gleeson M, Kentwell M, Meiser B et al (2020) The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients. Gynecol Oncol 158(2):431–439. https://doi.org/10.1016/j.ygyno.2020.05.001",
      "volume": "158",
      "year": "2020"
    },
    {
      "DOI": "10.1136/ijgc-2019-000630",
      "author": "L McLeavy",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "issue": "2",
      "journal-title": "Int J Gynecol Cancer",
      "key": "277_CR15",
      "unstructured": "McLeavy L, Rahman B, Kristeleit R et al (2020) Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. Int J Gynecol Cancer 30(2):221–226. https://doi.org/10.1136/ijgc-2019-000630",
      "volume": "30",
      "year": "2020"
    },
    {
      "DOI": "10.12968/bjon.2016.25.12.690",
      "author": "N Percival",
      "doi-asserted-by": "publisher",
      "first-page": "690",
      "issue": "12",
      "journal-title": "Br J Nurs",
      "key": "277_CR16",
      "unstructured": "Percival N, George A, Gyertson J et al (2016) The integration of BRCA testing into oncology clinics. Br J Nurs 25(12):690–694",
      "volume": "25",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.ygyno.2020.07.027",
      "author": "CB Powell",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "issue": "1",
      "journal-title": "Gynecol Oncol",
      "key": "277_CR17",
      "unstructured": "Powell CB, Laurent C, Ciaravino G et al (2020) Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. Gynecol Oncol 159(1):221–228. https://doi.org/10.1016/j.ygyno.2020.07.027",
      "volume": "159",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10897-018-0261-5",
      "author": "S Wright",
      "doi-asserted-by": "publisher",
      "journal-title": "J Genet Couns",
      "key": "277_CR18",
      "unstructured": "Wright S, Porteous M, Stirling D et al (2018) Patients’ views of treatment-focused genetic testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing. J Genet Couns. https://doi.org/10.1007/s10897-018-0261-5",
      "year": "2018"
    },
    {
      "DOI": "10.1136/jmedgenet-2020-107416",
      "author": "SY Yoon",
      "doi-asserted-by": "publisher",
      "journal-title": "J Med Genet",
      "key": "277_CR19",
      "unstructured": "Yoon SY, Wong SW, Lim J et al (2021) Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes. J Med Genet. https://doi.org/10.1136/jmedgenet-2020-107416",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.ygyno.2017.05.037",
      "author": "EM Bednar",
      "doi-asserted-by": "publisher",
      "first-page": "399",
      "issue": "2",
      "journal-title": "Gynecol Oncol",
      "key": "277_CR20",
      "unstructured": "Bednar EM, Oakley HD, Sun CC et al (2017) A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol 146(2):399–404. https://doi.org/10.1016/j.ygyno.2017.05.037",
      "volume": "146",
      "year": "2017"
    },
    {
      "DOI": "10.1038/s41431-020-0692-y",
      "author": "N Flaum",
      "doi-asserted-by": "publisher",
      "first-page": "1541",
      "issue": "11",
      "journal-title": "Eur J Hum Genet",
      "key": "277_CR21",
      "unstructured": "Flaum N, Morgan RD, Burghel GJ et al (2020) Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. Eur J Hum Genet 28(11):1541–1547. https://doi.org/10.1038/s41431-020-0692-y",
      "volume": "28",
      "year": "2020"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105140",
      "author": "B Rahman",
      "doi-asserted-by": "publisher",
      "first-page": "195",
      "issue": "3",
      "journal-title": "J Med Genet",
      "key": "277_CR22",
      "unstructured": "Rahman B, Lanceley A, Kristeleit RS et al (2019) Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet 56(3):195–198. https://doi.org/10.1136/jmedgenet-2017-105140",
      "volume": "56",
      "year": "2019"
    },
    {
      "DOI": "10.1038/s41598-020-60149-5",
      "author": "M Rumford",
      "doi-asserted-by": "publisher",
      "first-page": "3390",
      "issue": "1",
      "journal-title": "Sci Rep",
      "key": "277_CR23",
      "unstructured": "Rumford M, Lythgoe M, McNeish I et al (2020) Oncologist-led BRCA “mainstreaming” in the ovarian cancer clinic: a study of 255 patients and its impact on their management. Sci Rep 10(1):3390. https://doi.org/10.1038/s41598-020-60149-5",
      "volume": "10",
      "year": "2020"
    },
    {
      "key": "277_CR24",
      "unstructured": "Dutch Association of Medical Specialists (2020) Guideline breast cancer."
    },
    {
      "DOI": "10.1080/07357907.2018.1564926",
      "author": "DM Korngiebel",
      "doi-asserted-by": "publisher",
      "first-page": "39",
      "issue": "1",
      "journal-title": "Cancer Invest",
      "key": "277_CR25",
      "unstructured": "Korngiebel DM, Zech JM, Chappelle A et al (2019) Practice implications of expanded genetic testing in oncology. Cancer Invest 37(1):39–45. https://doi.org/10.1080/07357907.2018.1564926",
      "volume": "37",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s10897-017-0108-5",
      "author": "H Shipman",
      "doi-asserted-by": "publisher",
      "first-page": "1280",
      "issue": "6",
      "journal-title": "J Genet Couns",
      "key": "277_CR26",
      "unstructured": "Shipman H, Flynn S, MacDonald-Smith CF et al (2017) Universal BRCA1/BRCA2 testing for ovarian cancer patients is welcomed, but with care: how women and staff contextualize experiences of expanded access. J Genet Couns 26(6):1280–1291. https://doi.org/10.1007/s10897-017-0108-5",
      "volume": "26",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s11606-016-3943-4",
      "author": "JG Hamilton",
      "doi-asserted-by": "publisher",
      "first-page": "315",
      "issue": "3",
      "journal-title": "J Gen Intern Med",
      "key": "277_CR27",
      "unstructured": "Hamilton JG, Abdiwahab E, Edwards HM, Fang ML, Jdayani A, Breslau ES (2017) Primary care providers’ cancer genetic testing-related knowledge, attitudes, and communication behaviors: a systematic review and research agenda. J Gen Intern Med 32(3):315–324. https://doi.org/10.1007/s11606-016-3943-4",
      "volume": "32",
      "year": "2017"
    },
    {
      "DOI": "10.1200/JCO.2014.55.4576",
      "author": "W Eijzenga",
      "doi-asserted-by": "publisher",
      "first-page": "2998",
      "issue": "27",
      "journal-title": "J Clin Oncol",
      "key": "277_CR28",
      "unstructured": "Eijzenga W, Aaronson NK, Hahn DE et al (2014) Effect of routine assessment of specific psychosocial problems on personalized communication, counselors’ awareness, and distress levels in cancer genetic counseling practice: a randomized controlled trial. J Clin Oncol 32(27):2998–3004. https://doi.org/10.1200/JCO.2014.55.4576",
      "volume": "32",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.pec.2008.07.018",
      "author": "F Legare",
      "doi-asserted-by": "publisher",
      "first-page": "526",
      "issue": "3",
      "journal-title": "Patient Educ Couns",
      "key": "277_CR29",
      "unstructured": "Legare F, Ratte S, Gravel K, Graham ID (2008) Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals’ perceptions. Patient Educ Couns 73(3):526–535. https://doi.org/10.1016/j.pec.2008.07.018",
      "volume": "73",
      "year": "2008"
    },
    {
      "DOI": "10.1093/jnci/djz080",
      "author": "JR Vos",
      "doi-asserted-by": "publisher",
      "first-page": "161",
      "issue": "2",
      "journal-title": "J Natl Cancer Inst",
      "key": "277_CR30",
      "unstructured": "Vos JR, Fakkert IE, de Hullu JA et al (2020) Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition. J Natl Cancer Inst 112(2):161–169. https://doi.org/10.1093/jnci/djz080",
      "volume": "112",
      "year": "2020"
    },
    {
      "DOI": "10.1038/ejhg.2015.196",
      "author": "H Hoberg-Vetti",
      "doi-asserted-by": "publisher",
      "first-page": "881",
      "issue": "6",
      "journal-title": "Eur J Hum Genet",
      "key": "277_CR31",
      "unstructured": "Hoberg-Vetti H, Bjorvatn C, Fiane BE et al (2016) BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet 24(6):881–888. https://doi.org/10.1038/ejhg.2015.196",
      "volume": "24",
      "year": "2016"
    },
    {
      "DOI": "10.1136/jmedgenet-2016-103902",
      "author": "I Plaskocinska",
      "doi-asserted-by": "publisher",
      "first-page": "655",
      "issue": "10",
      "journal-title": "J Med Genet",
      "key": "277_CR32",
      "unstructured": "Plaskocinska I, Shipman H, Drummond J et al (2016) New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet 53(10):655–661. https://doi.org/10.1136/jmedgenet-2016-103902",
      "volume": "53",
      "year": "2016"
    },
    {
      "DOI": "10.1016/j.ygyno.2017.01.030",
      "author": "M Kentwell",
      "doi-asserted-by": "publisher",
      "first-page": "130",
      "issue": "1",
      "journal-title": "Gynecol Oncol",
      "key": "277_CR33",
      "unstructured": "Kentwell M, Dow E, Antill Y et al (2017) Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol 145(1):130–136. https://doi.org/10.1016/j.ygyno.2017.01.030",
      "volume": "145",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ygyno.2020.11.003",
      "author": "HQ Rana",
      "doi-asserted-by": "publisher",
      "first-page": "457",
      "issue": "2",
      "journal-title": "Gynecol Oncol",
      "key": "277_CR34",
      "unstructured": "Rana HQ, Kipnis L, Hehir K et al (2021) Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol 160(2):457–463. https://doi.org/10.1016/j.ygyno.2020.11.003",
      "volume": "160",
      "year": "2021"
    }
  ],
  "reference-count": 34,
  "references-count": 34,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-021-00277-7"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "21"
}